These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38641181)

  • 1. Retinal and choroidal changes after anti-VEGF therapy in neovascular-AMD patients: A systematic review and meta-analysis of SD-OCT studies.
    Salehi MA; Frounchi N; Zakavi SS; Mohammadi S; Harandi H; Shojaei S; Gouravani M; Fernando Arevalo J
    Surv Ophthalmol; 2024; 69(4):547-557. PubMed ID: 38641181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab.
    Sizmaz S; Kucukerdonmez C; Kal A; Pinarci EY; Canan H; Yilmaz G
    Eur J Ophthalmol; 2014; 24(6):904-10. PubMed ID: 24803153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.
    Rahman W; Chen FK; Yeoh J; da Cruz L
    Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1483-8. PubMed ID: 23160538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
    Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM
    Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
    Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
    JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Kanadani TCM; Veloso CE; Nehemy MB
    Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Cho HJ; Park SM; Kim J; Nah SK; Lee J; Lee DW; Kim JW
    Acta Ophthalmol; 2021 Jun; 99(4):e540-e546. PubMed ID: 32996674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
    BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
    ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
    Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Razavi S; Souied EH; Darvizeh F; Querques G
    Am J Ophthalmol; 2015 Nov; 160(5):1006-13. PubMed ID: 26275471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.